New Regulatory Regime For 8 Medical Items Under Drugs And Cosmetics Act

New Delhi : Adopting a proactive and sensitive approach to address the needs of the Indian Industry, the Union Ministry of Health & Family Welfare has taken a significant decision for ensuring continued access of eight regulated medical devices today.

The Ministry had earlier notified the following medical items to be regulated under the Drugs and Cosmetics Act which was to come into effect from 1st April, 2021 (as per S.O. 775(E) dated 08th February, 2019 under Medical Devices Rules 2017):

  1. All Implantable Medical Devices;
  2. CT scan equipment;
  3. MRI equipment;
  4. Defibrillators;
  5. PET Equipment;
  6. Dialysis Machine;
  7. X-Ray Machine; and
  8. Bone marrow cell separator.

Accordingly, as per the said order the importers/manufacturers are required to take import/manufacturing licence from Central Licencing Authority or State Licencing Authority, as the case may be, for import/manufacture of above devices, w.e.f. 1st April, 2021.

In order to ensure  supply chain continuity and access to these Medical Devices, while implementing  smooth transition into the new regulatory regime, Union Ministry of Health and Family Welfare has now decided that in case an existing importer/manufacturer who is already importing /manufacturing any of these devices, has submitted application to Central Licencing Authority or State Licencing Authority, as the case may be, for grant of import /manufacturing licence in respect of the said device(s) under the provisions of MDR, 2017, the said application shall be deemed valid and the importer/manufacturer can continue to import /manufacture the said device(s) up to 6 months from issue of this order or till the time, the Central Licencing Authority or State Licencing Authority, as the case may be, takes a decision on the said application, whichever is earlier. Order in this regard has been issued by Drugs Controller General (India) on 18th April 2021 through CDSCO website.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/04/MDnotice18-190421073032.pdf”]

  • Related Posts

    FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

    New Delhi: Food regulator FSSAI has suspended the licence of Dior Pharmaceuticals for multiple violations at its nutraceutical factory. In a social media post on Thursday, FSSAI observed “serious non-compliances”…

    Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

    Additional chief secretary (ACS), health, Sumita Misra said of these, 12 arrests have been made by FDA, Gurugram, which has also busted multiple interstate counterfeit medicine syndicates, seized fake medicines…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

    FSSAI suspends licence of Dior Pharmaceuticals for violations at nutraceutical plant

    Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

    Haryana intensifies crackdown on spurious drugs, FDA records 16 arrests in 10 months

    FSSAI Issues Prohibition Orders against FOLINEURO Syrup and Neuherbs TRUE VITAMIN over Misleading Claims

    FSSAI Issues Prohibition Orders against FOLINEURO Syrup and Neuherbs TRUE VITAMIN over Misleading Claims

    Pune Police Bust Illegal Bodybuilding Drug Racket, 5 Arrested; 50 Mephentermine Injections Seized In Major Crackdown

    Pune Police Bust Illegal Bodybuilding Drug Racket, 5 Arrested; 50 Mephentermine Injections Seized In Major Crackdown

    Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

    Piramal Pharma eyes mid-teens growth in FY27, prioritises organic expansion

    13 Years after Oxytocin Order, HC Seeks Compilance Status

    13 Years after Oxytocin Order, HC Seeks Compilance Status